ATOR-1017, a 4-1BB antibody developed for tumor-directed immunotherapy of cancer

被引：0
|
作者：
Werchau, Doreen [1 ]
Rosen, Anna [2 ]
Eriksson, Mia [1 ]
Jarnum, Sofia [1 ]
Furebring, Christina [1 ]
Smith, Karin Enell [1 ]
机构：
[1] Alligator Biosci AB, Lund, Sweden
[2] Alligator Biosci, Lund, Sweden
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P608
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ATOR-1017: A 4-1BB antibody designed for superior safety/efficacy profile in cancer immunotherapy
    Dahlen, Eva
    Rosen, Anna
    Barchan, Karin
    Dahlman, Anna
    Ellmark, Peter
    Furebring, Tina
    Smith, Karin Enell
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [2] ATOR-1017, A SECOND GENERATION 4-1BB ANTIBODY WITH POTENTIAL TO ENHANCE EFFICACY OF PD-1 THERAPIES
    Smith, Karin Enell
    Nilsson, Anneli
    Ellmark, Peter
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A595 - A595
  • [3] ATOR-1017, A 4-1BB ANTIBODY, DEMONSTRATES PROMISING SAFETY AND PROOF OF MECHANISM IN A FIRST-IN-HUMAN STUDY IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES
    Carneiro, Ana
    Ambarkhane, Sumeet
    Smith, Karin Enel
    Ullenhag, Gustav
    Schulz, Lena
    Landstrom, Tova
    Ellmark, Peter
    Carlsson, Malin
    Yachnin, Jeffrey
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A747 - A747
  • [4] A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies.
    Ullenhag, Gustav J.
    Yachnin, Jeffrey
    Carneiro, Ana
    Elison, Emma
    Carlsson, Malin
    Russell, Charlotte Astrid
    Smith, Karin Enell
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Initial findings from a first-in-human, multicenter, open-label study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies
    Ullenhag, Gustav J.
    Carneiro, Ana
    Smith, Karin Enell
    Schultz, Lena
    Ambarkhane, Sumeet Vijay
    Landstrom, Tova
    Yachnin, Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies
    Carneiro, Ana
    Hahn, Amanda
    Ellmark, Peter
    Enell Smith, Karin
    Schultz, Lena
    Ambarkhane, Sumeet
    Yachnin, Jeffrey
    Ullenhag, Gustav J.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (01)
  • [7] Role of 4-1BB:4-1BB ligand in cancer immunotherapy
    Adam T C Cheuk
    Ghulam J Mufti
    Barbara-ann Guinn
    Cancer Gene Therapy, 2004, 11 : 215 - 226
  • [8] Role of 4-1BB:4-1BB ligand in cancer immunotherapy
    Cheuk, ATC
    Mufti, GJ
    Guinn, BA
    CANCER GENE THERAPY, 2004, 11 (03) : 215 - 226
  • [9] Immunotherapy of Cancer with 4-1BB
    Vinay, Dass S.
    Kwon, Byoung S.
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (05) : 1062 - 1070
  • [10] Preclinical safety and efficacy of a tumor-directed T cell activating 4-1BB x 5T4 ADAPTIR™ bispecific antibody
    Dahlman, Anna
    Nelson, Michelle
    Bannink, Jeannette
    Johnson, Starrla
    Werchau, Doreen
    Nilsson, Anneli
    Ljung, Lill
    Blahnik-Fagan, Gabriele
    Bader, Robert
    Deronic, Adnan
    Ellmark, Peter
    Askmyr, Maria
    Hernandez-Hoyos, Gabriela
    McMahan, Cathy
    Fritzell, Sara
    CANCER RESEARCH, 2019, 79 (13)
12345